Gipfel Life Sciences GmbH

1 clinical trials · Sponsor

Record	Firm	Date
This Study Evaluates the Safety, Target Engagement, and Preliminary Efficacy of Galunisertib (TGF-βR1/ALK5 Inhibitor)Combined With Nerandomilast (PDE4 Inhibitor) in GREM2-positive ALS, a Biomarker-defined Subgroup Hypothesized to Reflect Heightened TGF-β/SMAD-driven Astrocytic and Fibrotic Signaling (NCT07321860)	Gipfel Life Sciences GmbH	2026-06-30

Every clearance here is in the API, with alerts when new ones post.